Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  AbbVie Inc.    ABBV

ABBVIE INC.

(ABBV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • For a short-term investment strategy, the company has poor fundamentals.
Strengths
  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • The company is one of the best yield companies with high dividend expectations.
  • Over the past year, analysts have regularly revised upwards their sales forecast for the company.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The stock is in a well-established, long-term rising trend above the technical support level at 84.34 USD
Weaknesses
  • Stock prices approach a strong long-term resistance in weekly data at USD 104.89.
  • Technically, the stock approaches a strong medium-term resistance at USD 104.99.
  • One of the major weak points of the company is its financial situation.
  • With an enterprise value anticipated at 5.69 times the sales for the current fiscal year, the company turns out to be overvalued.
  • For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
ABBVIE INC.18.30%184 916
JOHNSON & JOHNSON2.15%392 249
ROCHE HOLDING AG-4.55%287 762
PFIZER, INC.8.00%222 836
NOVARTIS AG-11.95%206 585
MERCK & CO., INC.-10.45%206 071
NOVO NORDISK A/S6.78%155 973
BRISTOL-MYERS SQUIBB COMPAN..-3.13%139 607
ASTRAZENECA PLC1.60%136 826
AMGEN INC.-5.87%132 100
ELI LILLY AND COMPANY9.65%130 647
SANOFI-7.35%126 752
GLAXOSMITHKLINE PLC-22.72%92 316
CHUGAI PHARMACEUTICAL CO., ..47.95%78 704
JIANGSU HENGRUI MEDICINE CO..23.39%72 683
DAIICHI SANKYO COMPANY, LIM..45.72%65 583
More Results
Financials (USD)
Sales 2020 45 620 M - -
Net income 2020 12 365 M - -
Net Debt 2020 74 496 M - -
P/E ratio 2020 25,6x
Yield 2020 4,51%
Capitalization 185 B 185 B -
EV / Sales 2020 5,69x
EV / Sales 2021 4,61x
Nbr of Employees 47 000
Free-Float 98,5%
Upcoming event on ABBVIE INC.
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes